Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Change in Interest Receivables (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Change in Interest Receivables for 3 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Interest Receivables fell 294.02% to -$2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$285000.0, a 115.91% decrease, with the full-year FY2025 number at -$285000.0, down 115.91% from a year prior.
  • Change in Interest Receivables was -$2.2 million for Q4 2025 at Nuvation Bio, down from $1.5 million in the prior quarter.
  • In the past five years, Change in Interest Receivables ranged from a high of $1.5 million in Q3 2025 to a low of -$2.2 million in Q4 2025.
  • A 3-year average of $66666.7 and a median of $241500.0 in 2023 define the central range for Change in Interest Receivables.
  • Biggest YoY gain for Change in Interest Receivables was 529.8% in 2025; the steepest drop was 294.02% in 2025.
  • Nuvation Bio's Change in Interest Receivables stood at $669000.0 in 2023, then tumbled by 185.05% to -$569000.0 in 2024, then crashed by 294.02% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Change in Interest Receivables are -$2.2 million (Q4 2025), $1.5 million (Q3 2025), and -$1.1 million (Q2 2025).